Centre for Psychedelic Research, Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, UK.
Eat Weight Disord. 2021 May;26(4):1265-1270. doi: 10.1007/s40519-020-01000-8. Epub 2020 Sep 8.
Psychedelic therapy is showing promise for a broad range of mental health conditions, indicative of a transdiagnostic action. While the efficacy of symptom-focused treatments for eating disorders (EDs) is limited, improved mental health and psychological wellbeing are thought to contribute to greater treatment outcomes. This study provides the first quantitative exploration of the psychological effects of psychedelics in those reporting an ED diagnosis.
Prospective, online data were collected from individuals planning to take a psychedelic drug. Twenty-eight participants reporting a lifetime ED diagnosis completed measures of depressive symptomology (Quick Inventory of Depressive Symptomology; QIDS-SR16) and psychological wellbeing (Warwick-Edinburgh Mental Wellbeing Scale; WEMWBS) 1-2 weeks before, and 2 weeks after a psychedelic experience. Twenty-seven of these participants also completed a measure of emotional breakthrough [Emotional Breakthrough Inventory (EBI)] in relation to the acute psychedelic experience.
Bayesian t tests demonstrated overwhelming evidence for improvements in depression and wellbeing scores following the psychedelic experience. Marginal evidence was also found for a correlation between emotional breakthrough and the relevant mental health improvements.
These findings provide supportive evidence for positive psychological aftereffects of a psychedelic experience that are relevant to the treatment of EDs. It is hoped that this will encourage further research and will bolster initiatives to directly examine the safety and efficacy of psychedelic assisted therapy as a treatment of EDs in future clinical trials.
Level III, cohort study.
迷幻疗法在广泛的心理健康状况中显示出前景，表明其具有跨诊断作用。虽然针对饮食失调（ED）的症状为导向的治疗方法的疗效有限，但改善心理健康和心理幸福感被认为有助于提高治疗效果。本研究首次对报告 ED 诊断的个体中迷幻药物的心理影响进行了定量探索。
前瞻性在线数据是从计划服用迷幻药物的个体中收集的。28 名报告有终生 ED 诊断的参与者在进行迷幻体验前 1-2 周和 2 周后完成了抑郁症状（快速抑郁症状清单；QIDS-SR16）和心理幸福感（沃里克-爱丁堡心理健康量表；WEMWBS）的测量。其中 27 名参与者还完成了与急性迷幻体验相关的情绪突破[情绪突破量表（EBI）]的测量。
贝叶斯 t 检验表明，在迷幻体验后，抑郁和幸福感评分有明显改善。还发现情绪突破与相关心理健康改善之间存在微弱的相关性。
这些发现为迷幻体验的积极心理后效提供了支持性证据，这与 ED 的治疗有关。希望这将鼓励进一步的研究，并为未来临床试验中直接检查迷幻辅助治疗作为 ED 治疗的安全性和有效性的举措提供支持。
三级，队列研究。
